Literature DB >> 25851553

ABO Group as a Thrombotic Risk Factor in Children With Acute Lymphoblastic Leukemia: A Retrospective Study of 523 Patients.

Terry Mizrahi1, Jean-Marie Leclerc, Michèle David, Thierry Ducruet, Nancy Robitaille.   

Abstract

Children with acute lymphoblastic leukemia (ALL) are at high risk of thrombotic complications, resulting from multiple risk factors (malignancy, chemotherapy, central venous access devices, and inherent host characteristics). Non-O blood groups have been associated with an increased risk of venous thromboembolism (VTE) in adults, with a compounding effect in the presence of thrombophilia or cancer. We hypothesized that among children with ALL receiving a standardized protocol, there would be an increased risk of thrombotic events in non-O compared with O blood group patients. In a retrospective study of 523 children with ALL from June 1995 to April 2013, there were 56 (10.7%) thromboembolic events. Patients with VTE were compared with the whole cohort, based on blood group, age, sex, leukemia phenotype, and clinical risk category. Among children with VTE, 42 (75%) had non-O and 14 (25%) had O blood group, compared with 302 (57.7%) non-O and 221 (42.3%) O blood groups in the cohort. Non-O blood group was confirmed as an independent risk factor for VTE in multivariate analysis. This is the first study to report a significant association between non-O blood groups and VTE in children with cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25851553     DOI: 10.1097/MPH.0000000000000333

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  5 in total

Review 1.  L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.

Authors:  Gaurav Goyal; Vijaya Raj Bhatt
Journal:  Future Oncol       Date:  2015-08-14       Impact factor: 3.404

2.  Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.

Authors:  Sarah M Kashanian; Noa G Holtzman; Ciera L Patzke; Jonathan Cornu; Alison Duffy; Madhurima Koka; Sandrine Niyongere; Vu H Duong; Maria R Baer; Jummai Apata; Farin Kamangar; Ashkan Emadi
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-07       Impact factor: 3.333

3.  Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.

Authors:  Rachid Abaji; Vincent Gagné; Chang Jiang Xu; Jean-François Spinella; Francesco Ceppi; Caroline Laverdière; Jean-Marie Leclerc; Stephen E Sallan; Donna Neuberg; Jeffery L Kutok; Lewis B Silverman; Daniel Sinnett; Maja Krajinovic
Journal:  Oncotarget       Date:  2017-07-04

4.  ABO blood groups and risk of deep venous thromboembolism in Chinese Han population from Chaoshan region in South China.

Authors:  Min Yu; Cantian Wang; Tingting Chen; Shuang Hu; Kaihong Yi; Xuerui Tan
Journal:  Saudi Med J       Date:  2017-04       Impact factor: 1.484

5.  Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma, nasal type: a triple-center study.

Authors:  Ya-Jun Li; Ping-Yong Yi; Ji-Wei Li; Xian-Ling Liu; Tian Tang; Pei-Ying Zhang; Wen-Qi Jiang
Journal:  Chin J Cancer       Date:  2017-07-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.